利用创新的纳米技术策略探索卵巢癌的替代生物标志物。
Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies.
作者信息
Castro Cesar M, Im Hyungsoon, Le Christine, Lee Hakho, Weissleder Ralph, Birrer Michael J
机构信息
Massachusetts General Hospital Cancer Center, 55 Fruit St, Yawkey 9E, Boston, MA, 02114, USA,
出版信息
Cancer Metastasis Rev. 2015 Mar;34(1):75-82. doi: 10.1007/s10555-014-9546-9.
Our increased understanding of ovarian cancer's blueprints (mediated by DNA and RNA) and behavior (mediated by proteins) points to wide differences across patients that cannot be depicted by histology alone. Conventional diagnosis usually entails an adequate tissue biopsy, which limits serial testing. There is thus a motivation to shift towards easier to obtain clinical samples (e.g., ascites or blood). In response, investigators are increasingly leveraging alternative circulating biomarkers in blood or proximal fluids and harnessing novel profiling platforms to help explore treatment-related effects on such biomarkers in serial fashion. In this review, we discuss how new nanotechnologies we developed intersect with alternative ovarian cancer biomarkers for improved understanding of metastases and therapeutic response.
我们对卵巢癌蓝图（由DNA和RNA介导）及行为（由蛋白质介导）的深入了解表明，患者之间存在广泛差异，仅靠组织学无法描述这些差异。传统诊断通常需要进行充分的组织活检，这限制了系列检测。因此，人们有动力转向更容易获取的临床样本（如腹水或血液）。作为回应，研究人员越来越多地利用血液或近端体液中的替代循环生物标志物，并利用新型分析平台以系列方式探索治疗对这些生物标志物的相关影响。在本综述中，我们讨论了我们开发的新纳米技术如何与卵巢癌替代生物标志物相结合，以更好地理解转移和治疗反应。
Zotero 插件